SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives

被引：18

作者：

Garla, Vishnu Vardhan ^{[1
,2
]}

Butler, Javed ^{[3
]}

Lien, Lillian F. ^{[1
]}

机构：

[1] Univ Mississippi, Med Ctr, Endocrinol Metab & Diabet, Dept Internal Med, Jackson, MS 39216 USA

[2] Univ Mississippi, Med Ctr, Mississippi Ctr Clin & Translat Res, Jackson, MS 39216 USA

[3] Univ Mississippi, Dept Internal Med, Med Ctr, Jackson, MS USA

来源：

CURRENT CARDIOLOGY REPORTS | 2021年 / 23卷 / 06期

关键词：

Sodium-glucose cotransporter-2 inhibitors; Heart failure; Hospitalization for heart failure; Major adverse cardiovascular events; Euglycemic diabetic ketoacidosis; COTRANSPORTER; 2; INHIBITOR; TYPE-2; DIABETES-MELLITUS; SODIUM; EMPAGLIFLOZIN; CANAGLIFLOZIN; INFECTIONS; MORTALITY; SAFETY;

D O I：

10.1007/s11886-021-01486-3

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Purpose of Review Heart failure is responsible for a significant part of diabetes-associated cardiovascular mortality and morbidity. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are novel agents approved for the treatment of diabetes mellitus; in recent clinical trials, these agents have shown a significant reduction in cardiovascular death and hospitalization secondary to heart failure. Recent Findings Clinical trials with specific heart failure outcomes have shown the benefit of SGLT-2 inhibitors in reducing the mortality and morbidity associated with heart failure. The guidelines for the management of diabetes mellitus recommend the preferential use of SGLT-2 inhibitors in patients with a history of cardiovascular disease. SGLT-2 inhibitors are potential game changers in the treatment of heart failure. Guidelines for prescription of these agents help assess risk-benefit analysis and personalize treatment for maximal benefit.

引用

页数：9

共 48 条

[1]

Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020 [J].

不详 .

DIABETES CARE, 2020, 43 :S98-S110

[2]

[Anonymous], 2019, IDF Diabetes Atlas, VNinth

[3]

[Anonymous], 2013, Diabetes

[4]

Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes [J].

Arakaki, Richard F. .

POSTGRADUATE MEDICINE, 2016, 128 (04) :409-417

[5]

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits [J].

Baartscheer, Antonius ;

Schumacher, Cees A. ;

Wust, Rob C. I. ;

Fiolet, Jan W. T. ;

Stienen, Ger J. M. ;

Coronel, Ruben ;

Zuurbier, Coert J. .

DIABETOLOGIA, 2017, 60 (03) :568-573

[6]

Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors A Review of Spontaneous Postmarketing Cases [J].

Bersoff-Matcha, Susan J. ;

Chamberlain, Christine ;

Cao, Christian ;

Kortepeter, Cindy ;

Chong, William H. .

ANNALS OF INTERNAL MEDICINE, 2019, 170 (11) :764-+

[7]

Cardiac effects of SGLT2 inhibitors: the sodium hypothesis [J].

Bertero, Edoardo ;

Roma, Leticia Prates ;

Ameri, Pietro ;

Maack, Christoph .

CARDIOVASCULAR RESEARCH, 2018, 114 (01) :12-18

[8]

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease [J].

Bhatt, Deepak L. ;

Szarek, Michael ;

Pitt, Bertram ;

Cannon, Christopher P. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Lewis, Julia B. ;

Riddle, Matthew C. ;

Inzucchi, Silvio E. ;

Kosiborod, Mikhail N. ;

Cherney, David Z. I. ;

Dwyer, Jamie P. ;

Scirica, Benjamin M. ;

Bailey, Clifford J. ;

Diaz, Rafael ;

Ray, Kausik K. ;

Udell, Jacob A. ;

Lopes, Renato D. ;

Lapuerta, Pablo ;

Steg, P. Gabriel .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (02) :129-139

[9]

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors [J].

Butler, Javed ;

Hamo, Carine E. ;

Filippatos, Gerasimos ;

Pocock, Stuart J. ;

Bernstein, Richard A. ;

Brueckmann, Martina ;

Cheung, Alfred K. ;

George, Jyothis T. ;

Green, Jennifer B. ;

Januzzi, James L. ;

Kaul, Sanjay ;

Lam, Carolyn S. P. ;

Lip, Gregory Y. H. ;

Marx, Nikolaus ;

McCullough, Peter A. ;

Mehta, Cyrus R. ;

Ponikowski, Piotr ;

Rosenstock, Julio ;

Sattar, Naveed ;

Salsali, Afshin ;

Scirica, Benjamin M. ;

Shah, Sanjiv J. ;

Tsutsui, Hiroyuki ;

Verma, Subodh ;

Wanner, Christoph ;

Woerle, Hans-Juergan ;

Zannad, Faiez ;

Anker, Stefan D. .

EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (11) :1390-1400

[10]

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes [J].

Cannon, Christopher P. ;

Pratley, Richard ;

Dagogo-Jack, Samuel ;

Mancuso, James ;

Huyck, Susan ;

Masiukiewicz, Urszula ;

Charbonnel, Bernard ;

Frederich, Robert ;

Gallo, Silvina ;

Cosentino, Francesco ;

Shih, Weichung J. ;

Gantz, Ira ;

Terra, Steven G. ;

Cherney, David Z. I. ;

McGuire, Darren K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15) :1425-1435

← 1 2 3 4 5 →